Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.38 |
| ▸ | AGER | Q15109 | 17/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1888274 | 1.00 | AGER (0.73) | AGERSLC6A4KDM4EMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL1888277 | 1.00 | AGER (0.73) | AGERSLC6A4KDM4EMAPK1TDP1 | |
| SCHEMBL1890014 | 0.99 | AGER (0.75) | AGERSLC6A4KDM4EMAPK1TDP1 | |
| SCHEMBL1577018 | 0.99 | AGER (0.75) | AGERSLC6A4KDM4EMAPK1TDP1 | |
| SCHEMBL1577020 | 0.99 | AGER (0.75) | AGERSLC6A4KDM4EMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL1889343 | 0.93 | AGER (0.71) | AGERSLC6A4 | |
| Hydrochloric Acid SCHEMBL1893690 | 0.93 | AGER (0.71) | AGERSLC6A4 | |
| Hydrochloric Acid SCHEMBL1889347 | 0.93 | AGER (0.71) | AGERSLC6A4 | |
| SCHEMBL1576892 | 0.92 | AGER (0.72) | AGERSLC6A4 | |
| SCHEMBL1576905 | 0.92 | AGER (0.72) | AGERSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | disclosed |
| US-9598375-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2470510-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMERS DISEASE. | TRANSTECH PHARMA LLC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140039025-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580833-B2 | Substituted imidazole derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP11B2, CYP2C19, SLC10A2 | SLC6A4 310/4885AGER 1632/4885KDM4E 2858/4885 |
| US-20140039025-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | MAPT, PSEN2, PSEN1 | SLC6A4 216/4885AGER 371/4885KDM4E 2205/4885 |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP3A7, CYP3A5, CYP3A43 | SLC6A4 273/4885AGER 3594/4885KDM4E 2721/4885 |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | CYP3A7, CYP3A5, CYP3A43 | SLC6A4 273/4885AGER 3594/4885KDM4E 2721/4885 |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | AGER, NOD2, PSEN1 | SLC6A4 1234/4885AGER 1/4885KDM4E 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.